Article
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
The oncologist - 1 Dec 2008
Wu Shang-Gin, Chang Yih-Leong, Hsu Ya-Chieh, Wu Jenn-Yu, Yang Chih-Hsin, Yu Chong-Jen, Tsai Meng-Feng, Shih Jin-Yuan, Yang Pan-Chyr
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations are usually detected in lung adenocarcinoma and are associated with a response to EGFR tyrosine kinase inhibitors (TKIs). However, not all EGFR mutations have similarly high clinical response rates. This study aimed to investigate the clinical characteristics and response to gefitinib in lung adenocarcinoma patients with complex EGFR mutations....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.